Why Innovent Biologics (SEHK:1801) Is Back In The Spotlight

Simply Wall St.10-24 13:38

Innovent Biologics (SEHK:1801) just reported positive Phase 3 data for its Claudin 18.2 targeted antibody drug conjugate, arcotatug tavatecan, in advanced gastric and gastroesophageal junction cancer....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2677901855?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","is_english":true,"pubTime":"2026-10-24 13:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2677901855","market":"sg","top_or_hot":-1,"title":"Why Innovent Biologics (SEHK:1801) Is Back In The Spotlight","media":"Simply Wall St.","content":"<div>\n<p>Innovent Biologics (SEHK:1801) just reported positive Phase 3 data for its Claudin 18.2 targeted antibody drug conjugate, arcotatug tavatecan, in advanced gastric and gastroesophageal junction cancer....</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/why-innovent-biologics-sehk1801-is-back-in-the-spotlight\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Innovent Biologics (SEHK:1801) Is Back In The Spotlight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Innovent Biologics (SEHK:1801) Is Back In The Spotlight\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-24 13:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/why-innovent-biologics-sehk1801-is-back-in-the-spotlight><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Innovent Biologics (SEHK:1801) just reported positive Phase 3 data for its Claudin 18.2 targeted antibody drug conjugate, arcotatug tavatecan, in advanced gastric and gastroesophageal junction cancer....</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/why-innovent-biologics-sehk1801-is-back-in-the-spotlight\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828714.EUR","symbol_name":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/why-innovent-biologics-sehk1801-is-back-in-the-spotlight","article_id":"2677901855","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/why-innovent-biologics-sehk1801-is-back-in-the-spotlight","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2677901855","pubTimestamp":1792820291,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Innovent Biologics (SEHK:1801) just reported positive Phase 3 data for its Claudin 18.2 targeted antibody drug conjugate, arcotatug tavatecan, in advanced gastric and gastroesophageal junction cancer. The results support a priority-review new drug application in China.\nDespite the clinical win, Innovent Biologics' 30-day share price return is down 19.54% and the 7-day share price return is down 6.57%, while the 3-year total shareholder return of 84.89% points to a much stronger longer-term...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU0149534421.HKD":"SCHRODER ISF HONG KONG EQ \"A\" ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0607220059.USD":"SCHRODER ISF HONG KONG EQUITY \"A\" (USD) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","01801":"信达生物","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK1583":"高瓴概念","KURE":"KraneShares MSCI All China Health Care Index ETF","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","BK1161":"生物科技","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1589":"北水核心资产","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1831875114.USD":"SCHRODER ISF ALL CHINA EQUITY \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币"},"translate_title":"信达生物 (SEHK:1801) 为何再次成为焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"KURE":0.6,"01801":0.9},"content_text":"Innovent Biologics (SEHK:1801) just reported positive Phase 3 data for its Claudin 18.2 targeted antibody drug conjugate, arcotatug tavatecan, in advanced gastric and gastroesophageal junction cancer. The results support a priority-review new drug application in China. Despite the clinical win, Innovent Biologics' 30-day share price return is down 19.54% and the 7-day share price return is down 6.57%, while the 3-year total shareholder return of 84.89% points to a much stronger longer-term picture that investors are weighing against the recent pullback. Capture how arcotatug tavatecan fits into the broader oncology opportunity set by comparing Innovent Biologics with our hand-picked 124 healthcare AI stocks that are building the next wave of data-driven drug development.\nInnovent Biologics has fresh clinical momentum and a long track record of shareholder gains, yet the share price just fell sharply over the past month. Does that pullback leave the stock looking mispriced, or fair for what you get today? AdvertisementPreferred P/E of 100x: Is it justified? Innovent Biologics closed at HK$83.20, yet the stock trades on a rich P/E of 100x that puts a clear premium on its earnings compared with peers. The P/E ratio compares the current share price to earnings per share and gives you a quick read on how much investors are willing to pay for each dollar of profit. For a research driven biopharma group like Innovent Biologics, a high P/E often reflects expectations for strong future earnings expansion and confidence in a growing commercial portfolio rather than current profits alone. That premium is not small. The P/E of 100x is far higher than the Hong Kong Biotechs industry average of 15.4x and also above the peer group average of 19.6x. This suggests the market is pricing in a much stronger earnings path than is implied for many competitors. It is even elevated against an estimated fair P/E of 37.2x. The current multiple therefore sits well above the level the market could move towards if sentiment cools or growth assumptions are revised. Explore the SWS fair ratio for Innovent Biologics. Result: Price-to-earnings of 100x (OVERVALUED) Still, a rich 100x P/E leaves Innovent Biologics exposed if key drug launches disappoint or if sentiment toward high-multiple biotechs cools suddenly. Find out about the key risks to this Innovent Biologics narrative. Another view on Innovent Biologics' value The rich 100x P/E paints Innovent Biologics as expensive, yet the SWS DCF model points in the opposite direction. At HK$83.20, the stock is described as trading about 46.1% below an estimated future cash flow value of HK$154.30. Two very different stories. Which one seems more realistic to you? Look into how the SWS DCF model arrives at its fair value. 1801 Discounted Cash Flow as at Oct 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Innovent Biologics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 192 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Sentiment feels split after weighing Innovent Biologics' rich valuation against its fresh trial success, so it makes sense to move fast and test the numbers yourself. To see what optimistic investors are focusing on, take a closer look at the 4 key rewards. Looking for more investment ideas beyond Innovent Biologics? If Innovent Biologics has your attention, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.  Target potential mispricings early by scanning a curated 192 high quality undervalued stocks that blend quality fundamentals with attractively low expectations baked into current prices. Strengthen your income game by reviewing a focused 226 dividend fortresses designed for investors who want high yields backed by real business substance. Sleep easier at night by filtering for 221 resilient stocks with low risk scores that score well on financial resilience and lower volatility across market cycles.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2677901855","isCrawlerRequest":true}